IRIS
TARTAGLIONE, Immacolata
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 717
NA - Nord America 640
AS - Asia 108
OC - Oceania 2
AF - Africa 1
SA - Sud America 1
Totale 1.469
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 636
IE - Irlanda 296
IT - Italia 191
GB - Regno Unito 66
DE - Germania 50
CN - Cina 48
SG - Singapore 42
UA - Ucraina 29
FR - Francia 23
GR - Grecia 21
SE - Svezia 11
BE - Belgio 9
PK - Pakistan 9
CH - Svizzera 7
FI - Finlandia 7
ID - Indonesia 3
TR - Turchia 3
AU - Australia 2
CA - Canada 2
CZ - Repubblica Ceca 2
NI - Nicaragua 2
BR - Brasile 1
ET - Etiopia 1
HU - Ungheria 1
IN - India 1
LU - Lussemburgo 1
NL - Olanda 1
PS - Palestinian Territory 1
RO - Romania 1
RS - Serbia 1
TW - Taiwan 1
Totale 1.469
Salva come PNG Salva come JPEG
Città #
Dublin 287
Chandler 122
Jacksonville 65
Caserta 43
New York 40
Princeton 38
Roxbury 38
Ann Arbor 36
Bremen 33
Singapore 28
Grumo Nevano 21
Cambridge 20
Medford 19
Beijing 18
Wilmington 17
Woodbridge 17
Naples 15
Ashburn 13
Des Moines 13
Boardman 10
Nanjing 10
Brussels 9
Milan 8
Napoli 8
Pozzuoli 8
Redwood City 7
Nanchang 6
Rome 6
London 5
Orlando 5
Fairfield 4
Helsinki 4
San Mateo 4
Munich 3
Tianjin 3
Aversa 2
Bandung 2
Brno 2
Elora 2
Kunming 2
Leawood 2
Los Angeles 2
Managua 2
Oxford 2
Pagani 2
Shanghai 2
Auburn Hills 1
Belgrade 1
Bologna 1
Brindisi 1
Cacule 1
Changchun 1
Council Bluffs 1
Florence 1
Francolise 1
Giugliano In Campania 1
Gravesend 1
Gunzenhausen 1
Hanover 1
Houston 1
Hyderabad 1
Imola 1
Jakarta 1
Jinan 1
Lahore 1
Luxembourg 1
Marano Di Napoli 1
Morgan Hill 1
Mountain View 1
Muro Lucano 1
Nanning 1
Ningbo 1
Nocera Superiore 1
Oberuzwil 1
Olbia 1
Padova 1
Poirino 1
Quarto 1
Ramallah 1
Sant'antonio Abate 1
Sarno 1
Seattle 1
Sevastopol 1
Shenyang 1
Taipei 1
Taizhou 1
Tettnang 1
Treviso 1
Turin 1
Wuhan 1
Totale 1.049
Salva come PNG Salva come JPEG
Nome #
Cognitive, Brain and Intracranial Artery Involvement in Beta Thalassemia 116
Effects of germline VHL deficiency on growth, metabolism, and mitochondria 84
Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major. 72
Hereditary hypochromic microcytic anemia associated with loss-of-function DMT1 gene mutations and absence of liver iron overload 71
Long-term improvement in cardiac magnetic resonance in β-thalassemia major patients treated with deferasirox extends to patients with abnormal baseline cardiac function 58
Asymptomatic intracranial aneurysms in beta-thalassemia: A three-year follow-up report 54
Long-term efficacy of deferasirox for cardiac siderosis in thalassemia major 51
Brain iron content in systemic iron overload: A beta-thalassemia quantitative MRI study 48
Long term efficacy of iron chelation therapy with deferasirox on endocrine function in thalassemia major 48
Clinical outcome of transfusions with extended red blood cell matching in β-thalassemia patients: A single-center experience 48
Auditory cortex hypoperfusion: a metabolic hallmark in Beta Thalassemia 48
A Novel 12q13.2-q13.3 Microdeletion Syndrome With Combined Features of Diamond Blackfan Anemia, Pierre Robin Sequence and Klippel Feil Deformity 47
BONE MINERAL DENSITY IMPROVEMENT IN PATIENTS WITH THALASSEMIA MAJOR ON LONG-TERM CHELATION THERAPY WITH DEFERASIROX 43
Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multicentre nation-wide cohort 43
Brain functional impairment in beta-thalassaemia: the cognitive profile in Italian neurologically asymptomatic adult patients in comparison to the reported literature 42
Recombinant erythropoietin vs. blood transfusion care in infants with hereditary spherocytosis: a retrospective cohort study of A.I.E.O.P. patients (Associazione Italiana Emato-Oncologia Pediatrica) 41
No evidence of increased cerebrovascular involvement in adult neurologically-asymptomatic β-Thalassaemia. A multicentre multimodal magnetic resonance study 41
Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with beta-thalassemia. 41
Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia. 40
An Analysis of Racial and Ethnic Backgrounds Within the CASiRe International Cohort of Sickle Cell Disease Patients: Implications for Disease Phenotype and Clinical Research 39
Age of first pain crisis and associated complications in the CASiRe international sickle cell disease cohort 38
A study of the geographic distribution and associated risk factors of leg ulcers within an international cohort of sickle cell disease patients: the CASiRe group analysis 35
Global geographic differences in healthcare utilization for sickle cell disease pain crises in the CASiRe cohort 34
Crushed deferasirox film-coated tablets in pediatric patients with transfusional hemosiderosis: Results from a single-arm, interventional phase 4 study (MIMAS) 33
Headache in beta-thalassemia: An Italian multicenter clinical, conventional MRI and MR-angiography case-control study 32
Tricuspid-valve regurgitant jet velocity as a risk factor for death in β-Thalassemia. 32
Hearing loss in beta-thalassemia: Systematic review 31
White matter volume changes in adult beta-thalassemia: Negligible and unrelated to anemia and cognitive performances 30
Italian patients with hemoglobinopathies exhibit a 5-fold increase in age-standardized lethality due to SARS-CoV-2 infection 30
No increased cerebrovascular involvement in adult beta-thalassemia by advanced MRI analyses 28
Non-transfusion-dependent thalassemia in Italy: less blues, no role of reds 27
Pain Burden in the CASiRe International Cohort of Sickle Cell Patients: United States and Ghana 23
Genome editing and cancer therapy: handling the hypoxia-responsive pathway as a promising strategy 19
Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies 19
Thalassaemia is paradoxically associated with a reduced risk of in-hospital complications and mortality in COVID-19: Data from an international registry 16
Mortality in β-thalassemia patients with confirmed pulmonary arterial hypertension on right heart catheterization 15
Risk factors for heart disease in transfusion-dependent thalassemia: serum ferritin revisited 13
Renal safety under long-course deferasirox therapy in iron overloaded transfusion-dependent β-thalassemia and other anemias 12
Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence 11
Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: Phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study 11
Brain perfusion changes in beta-thalassemia 6
Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia 5
Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial 4
Totale 1.579
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.167
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.167
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020155 28 11 5 5 13 9 22 3 14 4 35 6
2020/2021141 7 7 8 17 14 16 22 6 6 12 24 2
2021/2022279 6 4 5 4 61 10 31 25 18 7 20 88
2022/2023578 55 22 22 28 57 54 3 19 287 7 13 11
2023/2024235 19 7 18 14 63 47 4 5 5 0 19 34
2024/20252 2 0 0 0 0 0 0 0 0 0 0 0
Totale 1.579